Changes to the wholesale acquisition costs of four of the company’s insulin products will take effect in January 2024. Novo Nordisk stated in a news release that it will also bring down the price point of its unbranded biologics.
The news comes on the heels of a recent announcement from drugmaker Eli Lilly, which said March 1 it would cap insulin prices at $35 per month.
“We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes,” Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, said in a statement. “Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously.”
